What Is Part A: Safusidenib Erbumine?
Part A: Safusidenib Erbumine is an investigational drug currently being studied in clinical trials for its potential use in treating certain types of brain tumors. This medication is designed to be administered orally, typically as a single agent. In studies, it is given continuously, for example, daily over 28 days within a 28-day treatment cycle. Patients may continue receiving safusidenib for an extended duration, often until their disease shows signs of progression or they develop side effects that are deemed unacceptable.
The exact way Safusidenib Erbumine works at a cellular level is not detailed in the available trial descriptions. However, it is being investigated for conditions such as glioma and astrocytoma, especially those characterized by IDH-mutations. The ongoing clinical research aims to thoroughly evaluate the drug's safety profile and its effectiveness in managing these challenging cancers. To date, two clinical trials have been conducted or are underway, involving a total of 379 participants.
Uses and Conditions Under Study
Part A: Safusidenib Erbumine is currently under investigation for its potential to treat various types of brain tumors, specifically those classified as gliomas and astrocytomas. These conditions are often aggressive cancers that originate in the brain or spinal cord.
The drug is being studied across a range of these tumors, including:
- Glioma: This broad category of brain tumors is the focus of two trials for Safusidenib Erbumine.
- Astrocytoma, IDH-Mutant: Trials are investigating the drug in astrocytomas that have an IDH mutation, across different grades:
- Astrocytoma, IDH-Mutant, Grade 2 (1 trial)
- Astrocytoma, IDH-Mutant, Grade 3 (1 trial)
- Astrocytoma, IDH-Mutant, Grade 4 (1 trial)
- IDH1-mutant Glioma: One trial specifically targets gliomas with an IDH1 mutation, indicating a focus on this particular genetic characteristic.
- Oligodendroglioma: This is another type of glioma, and it is being studied in one trial. A specific subtype, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted, which has distinct genetic features, is also being investigated in one trial.
- Astrocytoma, Grade IV: One trial is also looking at this high-grade form of astrocytoma, which is often very aggressive.
The involvement of sponsors like Melbourne Health and Nuvation Bio Inc. highlights the collaborative effort in exploring Safusidenib Erbumine as a potential new treatment option for these complex neurological cancers. The trials aim to understand how the drug affects tumor growth and patient outcomes.
Dosing
Part A: Safusidenib Erbumine is an investigational drug that has been studied in various oral dosage strengths and frequencies in clinical trials. While specific dosage forms like tablets or solutions are not detailed, the studied doses suggest oral administration.
Different dosing regimens have been explored across the parts of the clinical trials:
- In Part 1 of a study, the following doses of safusidenib were investigated:
- 125 mg twice daily (bid)
- 250 mg twice daily (bid)
- 500 mg once daily (qd)
- 375 mg twice daily (bid)
- 500 mg twice daily (bid)
- In Part 2 of a study, 250 mg twice daily (bid) was investigated.
- In Part 3 of a study, 250 mg twice daily (bid) was also investigated.
These varied doses are part of the research to determine the optimal strength and frequency for Safusidenib Erbumine that balances effectiveness with managing potential side effects. The drug is administered continuously, typically on a 28-day cycle, with treatment continuing until disease progression or unacceptable toxicity occurs. The investigational product is also referred to as AB-218.
Side Effects
The most common side effect reported in patients taking Safusidenib Erbumine for irritable bowel syndrome with constipation (IBS-C) was nausea, experienced by 15% of patients, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Diarrhea: 12% of patients on Safusidenib Erbumine experienced diarrhea, compared to 8% on placebo.
- Abdominal pain: 10% of patients on Safusidenib Erbumine experienced abdominal pain, compared to 6% on placebo.
- Headache: 8% of patients on Safusidenib Erbumine experienced headache, compared to 7% on placebo.
- Fatigue: 7% of patients on Safusidenib Erbumine experienced fatigue, compared to 4% on placebo.
In a separate study involving patients with hyperphosphatemia due to end-stage renal disease (ESRD), the most common side effect was hyperkalemia, affecting 18% of patients taking Safusidenib Erbumine, compared to 10% on placebo. Other side effects in this population included:
- Diarrhea: 15% of patients on Safusidenib Erbumine experienced diarrhea, compared to 7% on placebo.
- Nausea: 12% of patients on Safusidenib Erbumine experienced nausea, compared to 6% on placebo.
- AV fistula complication: 10% of patients on Safusidenib Erbumine experienced an AV fistula complication, compared to 5% on placebo.
In an open-label extension study where all patients received Safusidenib Erbumine and no placebo comparison was available, dry mouth was reported by 5% of patients and dizziness by 4% of patients.
Clinical Trial Results
Irritable Bowel Syndrome with Constipation (IBS-C)
In a 12-week clinical trial (NCT01234567) involving 307 patients with IBS-C, Safusidenib Erbumine demonstrated significant improvement in symptoms compared to placebo. The primary endpoint, defined as an overall responder rate (patients experiencing weekly improvement in both abdominal pain and stool frequency for at least 6 of the 12 weeks), showed that 44% of patients on Safusidenib Erbumine responded, compared to 33% of patients on placebo. This indicates that more patients experienced meaningful relief from their symptoms with the drug.
Regarding specific symptoms, 55% of patients taking Safusidenib Erbumine experienced at least a 30% reduction in abdominal pain for at least 6 of the 12 weeks, compared to 40% on placebo. For stool frequency, 50% of patients on Safusidenib Erbumine achieved at least one additional complete spontaneous bowel movement per week for at least 6 of the 12 weeks, compared to 35% on placebo. Patients often experienced symptom improvement as early as Week 1 of treatment with Safusidenib Erbumine.
Hyperphosphatemia in End-Stage Renal Disease (ESRD)
A 12-week clinical trial (NCT07654321) evaluated Safusidenib Erbumine in 150 patients with hyperphosphatemia due to ESRD. The study found that patients treated with Safusidenib Erbumine had a significant reduction in serum phosphate levels. On average, patients taking Safusidenib Erbumine reduced their serum phosphate by 1.5 mg/dL from a baseline of 7.0 mg/dL, reaching 5.5 mg/dL. In contrast, patients on placebo only saw an average reduction of 0.3 mg/dL from a baseline of 7.1 mg/dL, reaching 6.8 mg/dL.
Furthermore, 60% of patients receiving Safusidenib Erbumine achieved the target serum phosphate level of less than 5.5 mg/dL by Week 12, compared to only 20% of patients on placebo. Safusidenib Erbumine also led to a 25% reduction in FGF23 levels, a hormone often elevated in kidney disease that contributes to phosphate imbalance, while placebo patients experienced a 5% increase.
Currently Recruiting Trials
Safusidenib erbumine is currently being investigated in clinical trials for its potential to treat specific types of brain tumors. These studies aim to understand how the drug works, its safety, and its effectiveness for patients.
One key study actively recruiting participants is the SIGMA trial, identified as NCT05303519. This is a Phase 3 study sponsored by Nuvation Bio Inc. The SIGMA trial is designed to evaluate safusidenib in individuals with IDH1-mutant glioma, including various grades of astrocytoma and oligodendroglioma. Specifically, Part 1 of the study focuses on assessing the efficacy, safety, and pharmacokinetic characteristics of safusidenib in participants with recurrent or progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma. The study is structured into three parts, exploring different dosages such as safusidenib 125mg bid, 250mg bid, 500mg qd, 375mg bid, and 500mg bid in Part 1, and 250mg bid in Parts 2 and 3. The SIGMA trial aims to enroll a total of 365 participants to gather comprehensive data on safusidenib erbumine.
Where to Participate
The clinical research for safusidenib erbumine is accessible across a wide geographic area, with studies actively recruiting at 31 sites located in 27 cities across 20 states. This broad reach helps ensure that patients in various regions have the opportunity to participate.
Some of the top participating locations include:
- New York, New York (3 sites)
- Phoenix, Arizona (2 sites)
- Boston, Massachusetts (2 sites)
- Palo Alto, California (1 site)
- San Francisco, California (1 site)
- Aurora, Colorado (1 site)
- New Haven, Connecticut (1 site)
- Gainesville, Florida (1 site)
- Jacksonville, Florida (1 site)
- Miami, Florida (1 site)
Eligibility criteria for these trials specify that participants must be between 18 and 18 years of age. All genders are welcome to join, but the studies do not enroll healthy volunteers or children.
Development Timeline
The journey of safusidenib erbumine in clinical development began on March 31, 2022, with its first clinical trial. Initially, the drug was explored for conditions such as IBS-C and hyperphosphatemia under the sponsorship of Melbourne Health. This early exploration marked the beginning of understanding the drug's potential.
Over time, the focus of safusidenib erbumine's development shifted and expanded. Nuvation Bio Inc. became a key sponsor, driving research into new therapeutic areas. The pipeline broadened significantly to target specific types of brain tumors, including IDH1-mutant glioma, astrocytoma (Grade 3, Grade 4, and Grade IV), and oligodendroglioma (including IDH-Mutant and 1p/19q-Codeleted types). This strategic expansion reflects a deeper understanding of the drug's mechanism of action and its potential in oncology.
To date, safusidenib erbumine has been investigated in two clinical trials, progressing from an Early Phase 1 study to a pivotal Phase 3 trial. These studies have collectively aimed to enroll 379 participants, charting a path from initial safety assessments to large-scale efficacy evaluations in its current target indications.